Zobrazeno 1 - 10
of 286
pro vyhledávání: '"Christian, Manegold"'
Autor:
Anetta Sulewska, Lothar Pilz, Christian Manegold, Rodryg Ramlau, Radoslaw Charkiewicz, Jacek Niklinski
Publikováno v:
Cells, Vol 12, Iss 6, p 905 (2023)
Epigenetic research has the potential to improve our understanding of the pathogenesis of cancer, specifically non-small-cell lung cancer, and support our efforts to personalize the management of the disease. Epigenetic alterations are expected to ha
Externí odkaz:
https://doaj.org/article/8b8526c8897a437a9d7a8c6764b96410
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9886acbf57f0bc41d9f3c6a77325893b
https://doi.org/10.1200/jco.22.02544
https://doi.org/10.1200/jco.22.02544
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::859d91608f4b04c049b1b2dc1a6776c2
https://doi.org/10.1200/jco.22.02542
https://doi.org/10.1200/jco.22.02542
Autor:
Heike Allgayer, Christian Manegold, Lothar R. Pilz, Erika Buchholz, Andrea Harms, Gordon B. Mills, Doris R. Siwak, Dennis P.M. Hughes, Laura D. Nelson, Irfan A. Asangani, Dessislava A. Nikolova
Supplementary Figure 2 from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d422492a2731f93dd9d5959a015dbae
https://doi.org/10.1158/0008-5472.22379933.v1
https://doi.org/10.1158/0008-5472.22379933.v1
Autor:
Heike Allgayer, Christian Manegold, Lothar R. Pilz, Erika Buchholz, Andrea Harms, Gordon B. Mills, Doris R. Siwak, Dennis P.M. Hughes, Laura D. Nelson, Irfan A. Asangani, Dessislava A. Nikolova
Supplementary Figure 3 from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35e23764df5033000449b4c1e174987c
https://doi.org/10.1158/0008-5472.22379930.v1
https://doi.org/10.1158/0008-5472.22379930.v1
Autor:
Heike Allgayer, Christian Manegold, Lothar R. Pilz, Erika Buchholz, Andrea Harms, Gordon B. Mills, Doris R. Siwak, Dennis P.M. Hughes, Laura D. Nelson, Irfan A. Asangani, Dessislava A. Nikolova
Supplementary Figure 1 from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f5a14f0d616fc0fb3356f38aa6539e1
https://doi.org/10.1158/0008-5472.22379936
https://doi.org/10.1158/0008-5472.22379936
Autor:
Heike Allgayer, Christian Manegold, Lothar R. Pilz, Erika Buchholz, Andrea Harms, Gordon B. Mills, Doris R. Siwak, Dennis P.M. Hughes, Laura D. Nelson, Irfan A. Asangani, Dessislava A. Nikolova
Cetuximab, which blocks ligand binding to epidermal growth factor receptor (EGFR), is currently being studied as a novel treatment for non–small cell lung cancer (NSCLC). However, its mechanisms of action toward metastasis, and markers of drug sens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12ad319933f44db603eb364c29c9b788
https://doi.org/10.1158/0008-5472.c.6499400.v1
https://doi.org/10.1158/0008-5472.c.6499400.v1
Autor:
Heike Allgayer, Christian Manegold, Lothar R. Pilz, Erika Buchholz, Andrea Harms, Gordon B. Mills, Doris R. Siwak, Dennis P.M. Hughes, Laura D. Nelson, Irfan A. Asangani, Dessislava A. Nikolova
Supplementary Figure 4 from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ea22578f404c134c7a2d6bd1753bc15
https://doi.org/10.1158/0008-5472.22379927.v1
https://doi.org/10.1158/0008-5472.22379927.v1
Autor:
Heike Allgayer, Christian Manegold, Lothar R. Pilz, Erika Buchholz, Andrea Harms, Gordon B. Mills, Doris R. Siwak, Dennis P.M. Hughes, Laura D. Nelson, Irfan A. Asangani, Dessislava A. Nikolova
Supplementary Figure 5 from Cetuximab Attenuates Metastasis and u-PAR Expression in Non–Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::998495c4d6cb48785e1fa9cd062b4ff6
https://doi.org/10.1158/0008-5472.22379924
https://doi.org/10.1158/0008-5472.22379924
Autor:
Paolo Pedrazzoli, Orazio Caffo, Silvia Novello, Nicolas Dickgreber, E. Stoelben, Alessandra Bearz, Michael Geissler, D. Ladage, G. Valmadre, Monika Serke, G.V. Scagliotti, Gerald Schmid-Bindert, S. Kurz, Frank Griesinger, I. Colantonio, Vanesa Gregorc, G. Borra, Valentina Monica, Gunther H. Wiest, Alessandro Follador, G. Folprecht, Alessandro Morabito, M. Schena, T. Wehler, Christian Grohé, Martin Reck, C. Kropf-Sanchen, C. Cauchi, Valter Torri, Anna Ceribelli, Luca Porcu, Christian Manegold, Antonio Santo, Rita Chiari, Luciana Irtelli, A. Meyer
Background Several strategies have been investigated to improve the 4% survival advantage of adjuvant chemotherapy in early-stage non-small-cell lung cancer (NSCLC). In this investigator-initiated study we aimed to evaluate the predictive utility of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95484bd5bd48f4904b2d77138f4c9c45
http://hdl.handle.net/2318/1814652
http://hdl.handle.net/2318/1814652